Virosomes for antigen and DNA delivery

Daemen, Toos; Mare, Arjan de; Bungener, Laura; Jonge, Jørgen de; Huckriede, Anke; Wilschut, Jan

doi:10.1016/j.addr.2004.09.005

Cited by 94 publications

(57 citation statements)

References 55 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The E7 protein was delivered using virosomes. 29,30 Figure 8a shows that an immunization with SFVeE6,7 after pre-injection with SFVLacZ admixed with E7-virosomes resulted in strong E7-specific CTL activation. Cytolysis was 86% at an E:T ratio of 30:1.…”

Section: T-cell Competition Involved In Genetic Immunizationmentioning

confidence: 99%

Viral vector-based prime-boost immunization regimens: a possible involvement of T-cell competition

et al. 2007

Self Cite

View full text Add to dashboard Cite

Vaccination with recombinant viral vectors may be impeded by preexisting vector-specific immunity or by vector-specific immunity induced during the priming immunization. It is assumed that virus-neutralizing antibodies represent the principal effector mechanism of vector-specific immunity, while killing of infected cells by vector-specific cytotoxic T lymphocytes (CTLs) has also been suggested. Using recombinant Semliki Forest virus (rSFV) expressing E6E7 antigen from human papillomavirus, we demonstrate that secondary immune responses against E6E7 are neither affected by vector-specific antibodies nor by CTL-mediated killing of infected cells. Instead, the presence of the antigen during the prime immunization appeared to be the main determinant for the boosting efficacy. After priming with rSFVeE6,7, a homologous booster stimulated the primed E6E7-specific CTL response and induced long-lasting memory. Passively transferred SFV-neutralizing antibodies did not inhibit E6E7-specific CTL responses, although transgene expression was strongly reduced under these conditions. Conversely, in mice primed with irrelevant rSFV, induction of E6E7-specific CTLs was inhibited presumably due to vectorspecific responses induced by the priming immunization. When during the priming with irrelevant rSFV, E7-protein was co-administered, the inhibitory effect of vector-specific immunity was abolished. These results suggest that, apart from vector-specific antibodies or killing of infected cells, T-cell competition may be involved in determining the efficacy of viral vector-based prime-boost immunization regimens.

show abstract

Section: T-cell Competition Involved In Genetic Immunizationmentioning

confidence: 99%

Viral vector-based prime-boost immunization regimens: a possible involvement of T-cell competition

et al. 2007

Self Cite

View full text Add to dashboard Cite

show abstract

“…90) Hydrogel nanoparticles have been utilized in the effective delivery of antigens, DNA and antisense oligonucleotides. [91][92][93] Cross-linked hydrogel nanoparticles (PVP-NP) (35-50 nm in diameter) composed of natural polymers offers targeting to intracellular sites and good acceptability because of higher water content.…”

Section: Solid Lipid Nanoparticles (Sln)mentioning

confidence: 99%

Nanocarriers: Promising Vehicle for Bioactive Drugs

Rawat

Singh

Saraf

2006

Biological & Pharmaceutical Bulletin

395

183

View full text Add to dashboard Cite

Development of new delivery systems that deliver the potential drug specifically to the target site in order to meet the therapeutic needs of the patients at the required time and level remains the key challenge in the field of pharmaceutical biotechnology. Developments in this context to achieve desired goal has led to the evolution of the multidisciplinary field nanobiotechnology which involves the combination of two most promising technologies of 21st century-biotechnology and nanotechnology. Nanobiotechnology encompasses a wide array of different techniques to improve the delivery of biotech drugs, and nanoparticles offer the most suitable form whose properties can be tailored by chemical methods. This review highlights the different types of nanoparticulate delivery systems employed for biotech drugs in the field of molecular medicine with a short overlook at its applications and the probable associated drawbacks.

show abstract

“…Virosomes are a special class proteoliposomes prepared from reconstituted infl uenza virus membranes supplemented with PC [ 56 ]. The physicochemical features of virosomes are constrained by their well-defi ned composition and method of preparation, but these vesicles benefi t greatly from the inherent delivery properties (effi cient cell binding, internalisation, and cytosolic release) and immunogenicity of the infl uenza virus.…”

Section: Cationic Liposomesmentioning

confidence: 99%

Functionalised Nanoliposomes for Construction of Recombinant Vaccines: Lyme Disease as an Example

et al. 2013

View full text Add to dashboard Cite

Liposomes (phospholipid bilayer vesicles) represent an almost ideal carrier system for the preparation of synthetic vaccines due to their biodegradability and capacity to protect and transport molecules of different physicochemical properties (including size, hydrophilicity, hydrophobicity, and charge). Liposomal carriers can be applied by invasive (e.g. i.m ., s.c ., i.d .) as well as non-invasive (transdermal and mucosal) routes. In the last 15 years, liposome vaccine technology has matured and several vaccines containing liposome-based adjuvants have been approved for human and veterinary use or have reached late stages of clinical evaluation.Given the intensifying interest in liposomebased vaccines, it is important to understand precisely how liposomes interact with the immune system and how they stimulate immunity. It has become clear that the physicochemical properties of liposomal vaccines -method of antigen attachment, lipid composition, bilayer fl uidity, particle charge, and other properties -exert strong effects on the resulting immune response. In this chapter

show abstract

Virosomes for antigen and DNA delivery

Cited by 94 publications

References 55 publications

Viral vector-based prime-boost immunization regimens: a possible involvement of T-cell competition

Viral vector-based prime-boost immunization regimens: a possible involvement of T-cell competition

Nanocarriers: Promising Vehicle for Bioactive Drugs

Functionalised Nanoliposomes for Construction of Recombinant Vaccines: Lyme Disease as an Example

Contact Info

Product

Resources

About